MNMD - Earnings call transcript Q3 2024 | Mind Medicine (MindMed) Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to Mind Medicine Third Quarter 2024 Financial Results and Corporate Update Conference Call.

[Operator Instructions]

This call is being webcast live on the Investors and Media section of MindMed's website at mindmed.co, and a recording will be available after the call. I would like to introduce Stephanie Fagan, Chief Corporate Affairs Officer at MindMed. Please go ahead.

Unknown Executive

operator. you, Thank everyone. Good afternoon, for Mine joining Financial a you today us Third Quarter of Med's and discussion XXXX Thank for Business Results. Highlights Chief call Rob the will Executive our Officer. Leading today Barrow, be by Dr. He will be joined Chief Dan Karlin, Officer; Medical our Commercial Lilienthal, and Officer. Francois Chief our prepared our will remarks, the we call After Q&A. for open call. for recording detailed release press in replay call also today's this audio An webcast be will the announcement conference and available as for online

about the today's product we statements including, be without and certain regulatory making candidates, cash runway our statements, safety, call, and plans, forward-looking potential clinical future During will prospects. anticipated of and efficacy expectations, limitation, progress and partnerships our

approval subject report XX-Q described and market various associated including the and made difficulties the processes. These such as regulators our other annual regulatory on filings XX-K filed SEC our research today. to risk Form factors These conditions, statements in with and are and applicable changes in Form the with and security are and Canadian risks development

Forward-looking nonoccurrence SEC statements the securities including made in the the made, filings estimates applicable and the significant and are statements the MindMed's opinions the management the assumptions, at course regulators of of the that of or normal are date risks with uncertainties occurring described are Canadian other events and of based on outside business.

obligation me to are You With change, are any law. cautioned such if as call update turn of made these which as November not the over reliance today, XXXX. that, except statements, undue by management's to disclaims to place statements forward-looking required X, MindMed let Rob. on views even

Robert Barrow

to incredible progress upon the anxiety generalized by pleased what NM-XXX-ODT for disintegrating We for of MM-XXX, of on or this MindMed, we and about or end execution everyone in the at major depressive our even third III initiate and first we year. disorder first study been to tablet, joining are programs study the and ODT, quarter, and share disorder, Stephanie, today. Phase III you, an our on excited or VOYAGE builds has Thank I'm the This for ahead our our Phase the MDD. more throughout lies year track half orally strong as called which GAD, to embarked year. for GAD remain our call of

also seen remain adults We called to GAD the second in in of century medical of a X the which U.S. our the called the have and innovation study XXXX. EMERGE our on in XX first first These little past indications NDD PANORAMA in study track study million significant III III Phase initiate half affect Phase quarter need. MMXXX-ODT MMXXX-ODT unmet together and approximately the represent of study and

health differentiated GAD believe offer approved, a positioning vision epidemic. first-in-class and potential the both believe significant deliver MMXXX-ODT of the our represents the ongoing transformational to treatment to a in transformational MDD treatment and if aspire patients we option change We compelling for in trajectory as needs could brain it targeting of and option that treatment psychiatry. We truly populations a has these potentially most unmet a of and best-in-class the a X

lie toward in and opportunities patients deliver bringing scale recognize that embrace potential. As we ahead we challenges the possibility progress the need, and MMXXX-ODT unique and that of this to

patients, MMXXX-ODT, potential significant approved, with to enthusiasm have a of in of the broad key and to date. for do undoubtedly While affirmed there the have medical prescribers, need other years, care sites the work stakeholders data we if of given the coming and generated is our unmet engagements the recognition

patients. disorders on the by need impact enormous to continuing on have are producing We unmet evidence these demonstrate this strong

showing that U.S. for the For September, Congress quality we of from XXXX an increases Wellness shared life worsen the small in National the ECMP Neuropsychopharmacology or patients. even analysis Survey in of example, significantly European the at GAD Health College severity of can and

at presented the Managed by we in hospitalizations, burden absenteeism productivity. a Pharmacy, significant Care month, economic last GAD Academy increases Additionally, and highlighting Nexus of in of reductions represented poster the overall XXXX major meeting

to progress engaging this our plans, the we body patient enabling needed goal stakeholders this with key As commercial potential bring the we evidence access continue into intend strengthening of and of with to reality.

Phase A to IIb development to that single development operationalize. few our to and a over to study. deliver which core trial by exemplified and our is decision principle our clear strategy under to call results to studies leverages III for unique FDA streamlined in the the highlight eliminate we replicate a dose turning early clean design development clinical like and earlier MM-XXX-ODT, efficient our of partnership designs our with rapid presented this principle III Phase This the after in Phase points is approach Therapy Designation Phase year about durable strong Before and program. psychotherapy Dan, IIb we MMXXX key aim by results which our observed the that response I'd bold are of Breakthrough

has and after trials heightened Safely psychodelics. obvious of effect of impact functional attention XXX ODT its have a clear administration. that perceptual amount for in several is methodological class other on A received matter the and recently a hours and drugs blinding

in and using including is studies, not receivable of expectancy reality These both drug. active. against clinically are Nonetheless, unmasking psychiatric psychiatry III assess approved arms these Phase central but treatment to and and nature raters common assignment blinded control considerations to our of that have virtually incorporating II qualitative several be our and effects are the this number, every additional include and of may functional methodological address unique intended across visit potential who to multiple strategies other programs. bias questionnaires and to we blind the While implemented

MM-XXX-ODT support believe both and our Our of of can we development effectiveness in the the with and and alignment on safety continued and interactions MTD. compelling further strategy and deliver rigor with FDA approach the our GAD design clear evidence

Phase efficient aligned closely given the of our and design across streamlined programs, protocols III anticipate and MDD of GAD both we the Operationally, patient for our both enrollment indications.

performing operational our inclusion by from Our our II enhanced Phase of sites Phase highest III many program. is in efficiency the of

planned Additionally, of as XX more benefit approximately IIb size and XX% than in our Phase which IIb will Phase from same months, enrolled having our we sample sites also Voyage the Voyage is the study. study

Our we clinical participants. attention enrollment a from protocols representative that specific are rapidly with sample operational sites input so recruit and designed to of enabling can

in entire and III on quality lead continue team that programs. the and efficiency momentum our clinical Our seek and to Phase field we organization execution of going into R&D to build

and by rapid III. sites continue believe progression the goals support enthusiasm of by invigorated trial expressed broad patients, seamless our execution are will in We enthusiasm and to this study and investigators Phase

Mine over Now the Med me Chief let call programs Dan? to turn Dr. discuss development more Medical clinical our detail. Officer Dan of in Karlin, to

Daniel Karlin

Thank you, Rob.

A or placebo. Each XXX and patterns Our and of to enroll group enroll durability X:X safety provide XX a receive Part development MM-XXX-ODT-XXX is randomized and to treatment XXX extension randomized participants anticipated for plan for will approximately X B Part micrograms, studies, clinical important to Voyage XX-week includes versus placebo. micrograms treatment approximately MM-XXX-ODT. for parts. to Panorama receive long-term participants, Panorama. study placebo. X or on MMXXX-ODTEXXX a opportunities randomized, period to GAD data MM-XXX-ODTXX consist the the anticipated parallel double-blind, Voyage X of placebo-controlled micrograms to is XX-week designed MM-XXX-ODT is is pivotal efficacy open-label assessing study with

unblinding In functional regulatory address date, MM-XXX-ODT and considerations clinical for as to to methodological such participant study accordance design our and to FDA guidance use with our key program selection. discussions complementary continues intended

doses, at assess a For not meaningful dose demonstrate Panorama, demonstrated that IIb arm they effect MM-XXX the This included accurately to XX have condition XX XX-microgram to doses, the on to true which example, response endiolytic been This in a builds supports randomized. our participants' the Phase that lower our we've blinding and ability approach where and we despite to micrograms a evidence of all is the tested clinical view response. treatment. functional did confound

placebo improvement over detect an XX% While have improvement both a almost based week been X-point voyage designed and to XX, for power statistical observed placebo assumptions. certain MMXXX have X-point over at previously on to we Panorama

III interim enhancing of size GAD nuisance results. increase for maintaining a studies both This or of unexpected design trial in studies will aged the MMA Phase each Phase of for study. blinded use criteria size adaptive recruit will Key in a HAM-A XX and which pooled and Additionally, rates dropout and response, our sample interpretability elements score as XX% with adjust exclusion statistical greater. parameters, with of an XX% specifically variability adults successful to in an such to allows diagnosis XX largely Both of GAD. MM-XXX our inclusion IIb mirror helps sample will up variances in approach power an reestimation, and

patient Part Phase rater eligible studies, monitor micrograms using or HAM-A with During up participants score reported for B central if be clinician-administered MMXXX-ODT-XXX our will will other assessed through Part of XX treatments and B. with to X their [indiscernible] investigators outcomes, treatment scales. available III higher reaches closely Participants electronic

the from design study Key effect, safety treatments. treatment will response per time treatments in need will longer-term patients. will be of in This allows repeated and of assessment B these an or for retreatment repeated of for treatment outcomes data response information also on to understanding the assess the to safety believe in durability efficacy, XXX we GAD we long-term Part and include of treatment to Importantly, the in average year the treatment, the dynamics MMXXX-ODT valuable

consistent to consist our IIb. baseline program the change is of XX, Panorama durability is measure. Voyage Phase are designed observed endpoint Phase both which successful be outcome the our using III primary Phase MM-XXXinGAD, for Overall, Ham-A we primary with and to including week in The as trial IIb the the from

initiate we data Part voyage the the of and Panorama Voyage Part track half A the As remain line of from study, top XXXX. half of the We in second of on the Rob anticipate year first Phase mentioned XXXX of initiate III half this of to in first XXXX. and in end A Panorama second earlier, from by

of MMXXX-ODT for to the MDD. Turning treatment

for group the an Depression baseline XXX-microgram Rating or from about point indication decision at in in to week effects. to expansion antidepressant observed Montgomery-Asberg MMXXX-ODT its for our Data of an study pipeline. our the pursue We GAD IIb, the dose Phase are II demonstrated from In given additional improvement XX.X excited potential as our MADRS XX. led MDD Phase our Scale we

endpoint major development will MADRS. a GAD, our in Like program clinical which pivotal appeared the MM-XXX to of program MDD effect episode a by III response depressive measured experiencing studies. as X point with encouraging are MADRS This advantage powered expect given X.X this study significant than X.XX. These would represented for we scores the a wasn't placebo, which baseline that was lower than over p-value less a that results were to and particularly the patients ceiling in statistically on the create Phase consist

Our will during placebo. EMERGE B, first parts. efficacy a XX-week parallel group of double-blind eligibility. extension XX-week Part single conditions period a open-label randomized to A, for MM-XXX-ODT, with And of which treatment treatment X assets be a MMXXX-ODT placebo-controlled safety study study will dose comprised eligible subject participants be for certain unique Part versus and of

least that diagnosis from anticipated endpoint The to EMERGE the to X Rob? in XXX to week receive randomized micrograms will design primary discussions. The call to MDD quarter MDD score second be MMXXX-ODP-XXX between over a the the Rob change turn EMERGE With is MADRS with of placebo. regulatory EMERGE results. I and X:X micrograms and discuss financial the enroll from of informed at additional third placebo. baseline primary and or at participants progress MMXXX-ODT-XXX be will study in timing back will by update,

Robert Barrow

Thanks, Dan.

operations million financial totaling results December quarter XX, September XX, and of cash ended XXXX. our equivalents of as XXXX. as $XXX.X believe million the ended XXXX, and our equivalents XXXX. quarter to will fund sufficient that our to compared for with September cash XX, $XX.X to the be cash cash Turning We We into

compared we that sufficient representing for XXXX GAD. first the runway in were million to months an data have our expenses ended Phase the XX, readout in $X and million September for believe line to top Research for cash of period at beyond $XX.X extend III least million. we Importantly, of quarter same XXXX, $XX.X the development our MIN-XXX-ODT XX increase the study

pivotal XX, related increase was Phase The XXXX, expenses and expenses MDD GAD ended result and AD to study We September to and million personnel decrease to General first an second quarter get for research study increasing development to in $X.X primarily was running. ramp of a $X.X of September for expenses million the decrease compared the expenses our in administrative and legal activities period and due to of increase commercial XXX million million. internal related XX, primarily in R&D costs net capacities program, The expense. our increase into ended up in up loss million. partially compared $X.X increases decrease attributable $X.X XXXX compensation III increase a in same of quarter $XX.X of XXXX, in offset to an were advancement related XXXX, $X.X MNXXX-ODT's million in million XX, of $X.X company's million as September do activities. was a expenses an studies preclinical $X.X in in and in ended of we lower $XX.X The for in as by Phase $X.X anticipate XXXX, III spending the increased the stock-based to the million, for million quarter to

people MindMed in few are key We XXXX X of warrants offering the to health innovation the III people and as successfully phase what maintaining by MindMed. bringing continued GAD closing, a in increase millions an on living for and fair our in advance believe several value focused at September and highly MDD. studies The issued expense. for option $X.X milestones offset next of was We and with and partially crisis studies our with us In novel will unites MN-XXX-ODT transformational The million, Phase decrease grow represents development our changes potentially treatment and out our due benefit significant completing brain III the in MM-XXX-ODT of capabilities believe differentiated continues Phase pivotal underwritten a primarily we value of growth is that and in entering forward record persist with we to strong execution success. key the build will track years. organization is drive research expected

all potential dedication deliver of that, team our their landscape reshape to joining to for like and I'd pipeline people I'm on questions. and you of the happy again we work for thank the take thank us living with therapeutic today, to to brain health team the disorders. our treatment of and are With I very your proud them want for efforts and as the

Operator

[Operator Instructions]

Goodman comes question first from Leerink from The Marc Partners.

Unknown Analyst

Madhu on that raters. for the really important radar Congress I is functional was of you and thought data site unblinding presented the line unblinding? Phase the for This How lack this program central recently the interesting Mark. is you unblinding the around at do that could fewer be of having showing something for think III impact in arms rater central blending approval? type And analysis central would

Robert Barrow

in much be for generated Certainly, set II question. Yes. overall to take Thanks submission. the component so the to data we're a trying important to going we our package an is Phase of

described II not mentioning, XX% or unsure that we Raiders of results, drug active So rating you're which the study, the for when in at the patient placebo. which look sake, received demonstrated Phase our events or whether as everyone's of being the

of data in are the study. And arms informative across all that a because where we X pretty a wrong arms. generally treatment particularly they distribution there uniform the were had was and guess, Those

was there the at And both with and a speaks on respond the evidence across consistent so but clinically patient endpoint. that at X for it clarity statistically study interviews as came unblinding out the as all uncertainty outcomes And only rate groups, structured in an look that primary the we isolation any didn't functional which significantly. of treatment somewhat saw level standpoint, the and to the we during from can groups impact the then the actually blending have functional unblinding

have certainly III would forward the change don't into program. dramatically expectation that, go that Phase we an we So as

psychiatry, common blinding, we call, the I for our and reality the functional during extremely mentioned psychiatry blinding is in think every [indiscernible] virtually on data drug. functional as Those

we statistical area the kind clinically is an certainly agency anticipation and -- while is over informative, the of development demonstrate focus so the develop need be and same -- doing should and the our standard And increased of the supportive as all difference we will the These of regulatory end of show of our meaningful program. the scrutiny in which what be to but continued previous a placebo. and with and effectiveness day, at and the discussions to of to held so drugs, safety drug

Operator

question Abrams from Markets. RBC next Our comes Brian Capital from

Unknown Analyst

Brian. Nevin for This is on

then psychotic perhaps this or in So commentary seeing. had are were following concerning recruitment due an as to might indication-specific that they you friction of issues you and recent trial maybe NGAD? difficulties drapes that finding how -- some be some having that you spaces with be and do specific the think difficulties and from foresee competitor initiate given enrollment that problem in mentioned depression trial another some to to look there Do then reduce surrounding And any Panorama Voyage you specific appointments design, getting some any difficulties? might looking in they particular

Robert Barrow

Great question.

cannot say enough to for study, our they these field the at when set and GAD Even unable pace operationalize set have the expect any and say field and team faster Phase that which to to we standard II we've development standard clinical certainly in protocols. enroll how study, with Our the was will hands-on we team, we a and in close look our we I I incredibly it way. about back can study clinical well the seen our really in engagement than sites. for very that other the plan continue all virtually were of

patients get that context really these up experts team and have navigate why are execute get -- but of our set for those studies, that's dosing. logistical certainly to to sites scheduled with and seamlessly the there challenges on the ability We and have we

in seen of the we success indicate II. other than in study continuation not anything change we would that enrolling had the a Phase So have any

go study that, sites. we again, XX which had same building when XX we the around we as so size sites the in on VOYAGE study, our II I And as have forward, where is Phase continue

there, of sites same So patients. we'll only have even additional number the while targeting

trials screened We But an site go in degree And instances, that when but we there's same and for also greatest got the the but us our a length gives indication that those ease central the us both a a a could to of these a GAD board, NBD us allows and engagement instance, programs great high are, think operationalize in across choice to major so efficiency markets, studies from sites also after the patients of moved standpoint, many us into getting -- a going in the degree of those and are broader depressive general and campaigns. everything impressive commercial a in patients access from after intentional having allows study. MDD to by population that who studies. the for our and general opportunity made episode into local at MDD across then both recruiting was dynamic the about running JD over disorder these largest the for be also then to up screened have patients, it

we So everything Phase with it quality the go design -- again, efficiently continue we possible as II. about to we'll intended how quickly that the to and every the expectation in study forward operationalize executing through go highest is

Operator

Our Duncan next from from comes question Cantor. Charles

Charles Duncan

have pacing. you're using I follow-up was the Rob would does them some to LST. quite last question helpful. designs be one, you what regarding are sites, anticipate? evaluating thanks did of and naive guess on somewhat enrollment -- to all trial I to like a is more and information that but the team, going seem It that for the

a it back what to the study could I than experience, for guess time that even so showed you enroll? go And to assume Phase in frame could first similar you pace quickly Ib Or you the round. more voyage think if

Robert Barrow

much, Charles. Thanks so

the particular. we're from in to hopefully XXXX. both other our excited something trying of Phase the first streamline in is That be that half up course, enrollment And the the at every in is we track opportunity doing running, the I and is believe enthusiasm getting and top the an III accelerate study execute and So we the and second the of are about guidance from on X see team that for of also to of for line XXXX. will, readout and A we we'll would study, half have the study first investigative studies be of potential job participants Part these do sites but incredible think sites in certainly

enrollment certainly specific while So a given any we studies. on in on great we're to to believe month, and position these can't track rates execute really speak on we

Charles Duncan

mentioned analysis? analysis design, interim of for using correctly, that there for a that If number an power would I other Dan milestone. of the interim you that patients? adaptive was triggers give interim an heard be he what useful an some conditional us sense Could

Robert Barrow

high really market say those generally with line and we would that studies halfway enrollment somewhere the a be sort around At I'd are typically, generically, time analyses the level, in think of done time of certainly line. we

time to about we the So beginning a reestimation conduct would size half there's participants of at slight increase look study. of to required in a the a blinded we've maintain determine blinded fashion, sample and established power reasonable the sample a size if in that roll be take the the

Charles Duncan

the patient sample GAD you that intend And or my regarding is final that -- population enroll. question then to

XX I to restricting on as of you phenotypic, information Ham-A prior you enrollment But it, duration any therapies? track those pieces think or greater such and are required. And or are mentioned planning either characters. other phenotypic of of Dan being onset call symptom

Robert Barrow

turn this I'll Yes. Dan. to one over

Daniel Karlin

for to the question, Charles. Thanks hear you. Nice from Yes.

someone treatment we come would those, of a detailed So, be need as history. at we ton details, treatment Certainly, the tapered be the absolutely off. is more while erotypic a other for screening XX, with treatment certainly, to HAM-A criteria get set might to of history but will including aware track the enrollment we

thing. are treatments that this both what So treatments have duration they some in had and those of their sort number and of

or exclusion be that performance will criteria, as like the on we drug the phenotypic to inclusion data a look while able we at prior don't So of based entry. use at certainly treatment

Charles Duncan

Or it IIb? details, to in even any of phenotypic those enrollment call or efficacy drivers the Phase

Daniel Karlin

design the Phase of recall IIb arm basis. the per per arm You'll on small pretty that a $XX

while try and weren't can. our work out we of slice and group can't But response anything the down we to way any So data we of difference detecting in base we to, we any tease course, with those sizes predictors there.

Operator

question Brisebois from from comes Oppenheimer. Next Francois

FranÃ§ois Brisebois

wondering, this Part just chance, Part thought before And there was kind reading the then is for a A? I classic I is follow-up. it have of data Or any out? waiting and out about B Part have read A a happens, you you

Robert Barrow

Yes. and -- once the to for we Thanks, XX-week top database of portion the we out that Frank. No, study to intend line portion there. study of complete results the our read the lock

any certainly, on do patients blinding results. and group certainly in or study provide study capability an they patient received telling an we anticipate in will the So basis not those like analysis we to on, the while lock and A patients what continue have of individual of and Part the

FranÃ§ois Brisebois

And prior where can either this to the good -- things any the is are that and early is not could stoppage? on whether final? this there anyway Okay. question of trigger prior an readout and reason it off or looking are how you for riffing you're blind great not could going from this things trigger some the trigger you stoppage or sort stop that there is kind way here, an Like interim interim can Charles Great. of -- readout, kind the early of a

Robert Barrow

making of versus design, HAM-A question another. made. power testing We the baseline make assumptions reduce parameters and variance we've enrollment, that distribution in nuisance is response actual nuisance those the simply the scores from realized Thanks the doesn't that or so blinded study. reestimation this that No, that look group's -- right, that spend point simply to Dan are for a one the actual parameter inferential no alpha the at rate interim there's sure consistent sure We're anything adaptive in the that the mentioned, happens. or the with pooled the that dropout about of the don't at

for efficacy test or alpha testing be virtual time. during any won't we early So or that futility at a spending

FranÃ§ois Brisebois

to and I then on if And elections want thoughts on the this, Great. it to or space? can what lastly, willing comment the don't but and you're any do know

Robert Barrow

in certainly been with political have an and health federal Yes. engagement and many brain awareness officials No. of local the It's mental eventful and government the state broad both impact We've seen in branches broad week. level, of and health the had of this having broad disorders broad enthusiasm and that could burdensome so and certainly and really country engage grown see health depression, patients anxiety on willingness public a in we and a to being from potential standpoint, this substantially represent. for

Operator

[Operator Instructions]

next question. Our

next Patrick Trucchio Wainwright. comes from Our question H.C. from

Patrick Trucchio

on all Congrats the progress.

trial? regulatory to able one discussion potential trial? curious just single Voyage just to is The program. you would from a to looking question what the first provide the just just to question expect trial? the move And MDD forward Phase -- readout is extent is there possibility the I'm a you to on III additional are what learn read-through be the PANORAMA And from regarding just with second III second you might the Phase

Robert Barrow

Yes. have studies. second we study. of be design certainly for opportunities the On say just that further anticipate timing that to accelerate always our exploring what We that plans the point, but will programs, doing X exact and and I'll look latter in we'll will place certainly

the depression terms interactions, with for those study across in in especially would indications, -- matter we is we standpoint it's submission indication. have of the a a be that regulatory ensuring required aligned In what but programmatic complete from alignment second that of that simply for

get at exact be announcing timing certainly and we design on that clarity that and the study, unfolds of later So we'll as as date. that a

want of We build results body saw a terms certainly, see of demonstrate as to study. from Phase in response. continue the evidence II as compelling and to read-through, hopefully and we as consistency And of we

certainly Phase the with that across II our complementary I programs. we're using III think designs and

promising consistent We response want And have the see ideally extent conducting to we're Phase build Phase and that. confidence continue that III, conducted X to everywhere continued in we from really we'll a X-arm certainly studies our now first study we MMXXX. a to in we Phase to in arm And from that II. see the response II see X we of our results to repeatability

Patrick Trucchio

and just Right. a with discussion with And just just the far that then bias? if data, showing can XX-week from guess, I of and response the dose earlier. could, VOYAGE as blinding the talk help blinding curious other this a of data trial, I'm long-term kind and the follow-up of as around on just any functional particularly functional in how just extension -- addressing in could the the -- question importance you I question follow-up sort terms about also of

Robert Barrow

Yes.

So functional occurs and clear blinding with I It perceptual effect. occur. with drugs unblinding psychiatry a coming trial, think the will every certainly functional in

We the individual try of think comprehensively believes so have the for question that addressing the these program, who field no do idea active that that full really What program designs we're dose they will to but -- across likelihood anyone studies. have take there's drug also patients in I use the across within don't we on average. that a complementary is

which moving dose study with Phase the forward What was we statistical established III. taking a with in dose dose, have we're II and into and that that XXX-microgram Phase response response indicated clinical we significance

demonstrated saw significance also has placebo. versus comparison pairwise that XXX-microgram We the the

rigorously the new So have we're XXX. establish of response dose very confident we that the

connectivity a but study someone to in as lower used or intended really As forward, to Panorama is Panorama dose the being mitigate is background shown the clearly we by active, being clinical and by study functional there, confuse between we've bias III lower but that II and may Phase it dose which clinically Phase outcomes, second control expectancy would expectancy a in lower is the not have an is there, in little go mediated dose dose is knowing the secondary that but this perceivable, unblinding. getting entering used

And program. it view, to increase aims it, the across the the so integrity doing again,

that in Now we've Phase already II. done

we've different controls with Phase that do So end a allocation day, the to binding feel ratios by in the drug the program available in the body a of and seeing is a that at support seek evidence based II data III across on field that is that that and of that building date again, feel we functional effect. data, anyone the seeing program. there, conclusion, X have But what highly to and best simply we'll to we driven true on response that Phase are continue the studies different we're not observed to certainly, confident full we

Operator

Group. Our next Maxim comes from from question McCarthy Jason

Michael Okunewitch

Okunewitch. This Michael is

have So just side MM-XX psychedelic the like -- with any bit there approved on guess little likely delivery ahead to another significantly delay, is since of on no long-acting I a we're ask Compass' to market added data the delivery me, for of the and to that infrastructure. risk one expansion longer I'd drive

Robert Barrow

we'll regardless of with other payers excited field. be all again engagements or and are Yes. say pursuing to question, execute to and as and eager to sites team's clinical those the and that's field of and the we that other extremely the confident the and we we'll able continue something been something standard to standard we've this we're believe in Thanks against here, programs certainly, the Michael. real-world in be for But what the programs delivery happens for be else for the our terms is I'd shaping market progress key pursuing very ability organizations. stakeholders development as of with to set

Michael Okunewitch

no that of number the having could psychotherapy able you're settings that potentially anticipate you broaden delivery components into? go to Do

Robert Barrow

both results, a clinical can certainly of day. access the for at that how was also and we of the end maximize to interpretability of It we driver integrity try the patients but for deliver of the making decision, have to

are delivery the to the patient have impact it's MM-XXX and a opportunity by access for to modality, design intended we broad it's pursuing deliver maximize the what how on trajectory we disorders. is and these So intentional, of

Operator

Our next question comes Canaccord from Calian Genuity. from Sumant

Sumant Kulkarni

In used? attributable that the your GAD open-label the might maintain XX-week how remind of could be to effect in us be extension other the integrity versus durability will program, XXX you medications solely an trials, of that you may

Robert Barrow

one to Dan. turn I'll that over Yes.

Daniel Karlin

the portion. for randomized, same to Thanks because given no making additional the CMEs to first we go that we're Sumant. not at will have need question, these it, on treatment the driver on available will the folks fortunes. for of trials use controls to that it's double-blind real extension same for as is we phase restriction participants be back as -- there who think The period

Sumant Kulkarni

want of in a real in optimal out level the that guess, map with to therapy then it. does I you setting. -- to rescue And XXX Got be considered what the if to this redosing clinical world, involve not any, be trial if might

Daniel Karlin

else following adequately not if question? asking, could Is be responding I'm what that was the someone they given? you're the So if

Sumant Kulkarni

many respond responders, kinds be would going does That events that. Clearly, then those if how all exactly. But there's Yes, characterize some of you of someone you and needs out to rescue, that? do expect? how nonresponders always and of

Daniel Karlin

Yes.

and upshot that they up X of treatments open-label part, subsequently period. phases during response, to that the loses that somehow extension XX-week get can if So the

particulars and It's any So everybody that, it who the doesn't trial there doesn't and completely have to responding they study. use to study how people first Well, to the severe no and comfortable good missing data that's respond, that the matter they everybody from be people. that enough treat redosing going not is, ultimately step need something and else. be and would they things drug withdrawn are are are right? it captures be after illness would need methods statistical the your the treat for are don't try and Then

the in folks the stay having that that hope So with, IPAs, the treatment course, themselves. along that study. options is is whole But made certainly, able a are open-label by by these that's decision participants to of

Operator

does in I you your today's conclude am conference. This questions. the program. for you Thank showing further Thank participation no

now disconnect. You may

Mind Medicine (MNMD) 7 Nov 242024 Q3 Earnings call transcript